Schizophrenia: all 3,539 studies

Page 24 of 36. Open to participants first (473), then studies with results posted, then the rest; newest registration first within each.

• F17464 in Acute Schizophrenia TrialCompletedNCT02151656Phase 2
• Testing Effect and SchizophreniaCompletedNCT02150174Not applicable
• Examining Dose-Related Effects of Oxytocin on Social Cognition Across PopulationsTerminatedNCT02149823Phase 1
• European Long-acting Antipsychotics in Schizophrenia TrialCompletedNCT02146547Phase 4
• The Efficacy and Safety of Quetiapine XR in Patients With Schizophrenia Switched From Other AntipsychoticsCompletedNCT02142556Phase 3
• Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With SchizophreniaCompletedNCT02137993Phase 4
• Evaluation of Social Skills Intervention on Cognitive Function in SchizophreniaStatus unknownNCT02134418Not applicable
• Real Life Assessment of Abilify MaintenaTerminatedNCT02131415
• Integrated Metacognitive Therapy in First Episode PsychosisCompletedNCT02131116Not applicable
• Intensive Transcranial Magnetic Stimulation for Negative Symptoms in SchizophreniaStatus unknownNCT02127879Not applicable
• Remote Cognitive RemediationCompletedNCT02121106Not applicable
• Schizophrenia Cognition Scale DevelopmentCompletedNCT02118571
• Efficacy Study of GAÏA Program Cognitive Remediation of Facial Affects Processing in SchizophreniaCompletedNCT02110771Not applicable
• Exploration of Neural Bases in Social CognitionStatus unknownNCT02110017Not applicable
• Retrieval Practice and SchizophreniaSuspendedNCT02108899Not applicable
• Optimizing Cognitive Remediation Outcomes in SchizophreniaCompletedNCT02105779Not applicable
• Repetitive Transcranial Magnetic Stimulation (rTMS) as an add-on Treatment for Resistant Obsessive-compulsive Symptoms in Patients With SchizophreniaCompletedNCT02105064Not applicable
• Probing the Cannabinoid System in Individuals With a Family History of PsychosisActive, not recruitingNCT02102113Early Phase 1
• Association of Amisulpride Response in Schizophrenia With Brain ImageStatus unknownNCT02095938Phase 4
• The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic SyndromeStatus unknownNCT02093858
• Bioavailability of LY03004 and Risperdal® Consta®CompletedNCT02091388Phase 1
• Health Promotion and Fitness for Younger and Older Adults With SMICompletedNCT02090335Not applicable
• Effects of CDP-Choline on Gating and Cognitive Deficits in First Episode SchizophreniaStatus unknownNCT02088983Phase 2
• A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic PatientsTerminatedNCT02088060Phase 2
• Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric ParticipantsCompletedNCT02087579Phase 1
• Implementation of Illness Management and Recovery in Mental Health ServicesCompletedNCT02077829Not applicable
• Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ERCompletedNCT02075528Phase 4
• RCT of Methotrexate Added to Treatment As Usual in SchizophreniaCompletedNCT02074319Phase 1
• Bioequivalence Fasting Study in PatientsCompletedNCT02072954Phase 2/3
• STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.CompletedNCT02069925Not applicable
• Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With SchizophreniaCompletedNCT02062190Phase 2
• Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT02055287Phase 1
• Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction StudyCompletedNCT02051387Phase 1
• Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or SchizophreniaCompletedNCT02050854
• Electroconvulsive Therapy (ECT) in Patients With Super Refractory SchizophreniaStatus unknownNCT02049021Phase 4
• Tandospirone Combined With Atypical Antipsychotic Drugs in SchizophreniaStatus unknownNCT02040883Phase 4
• Cognitive Remediation of Autobiographical Memory in Schizophrenia Using SenseCam®Status unknownNCT02038465Not applicable
• Integrated Care Including Assertive Community Treatment in Early PsychosisCompletedNCT02037581Not applicable
• Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical AntipsychoticsCompletedNCT02037074Phase 1
• Glutamate, Brain Connectivity and Duration of Untreated PsychosisCompletedNCT02034253
• The Effect of Sertindole and Risperidone on Endophenotypic Markers of SchizophreniaTerminatedNCT02021201Phase 4
• Very Low Nicotine Cigarettes in Smokers With SchizophreniaCompletedNCT02019459Phase 2
• A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on RisperidoneCompletedNCT02019329Phase 1
• Adjunctive Aripiprazole in the Treatment of Risperidone-Induced HyperprolactinemiaStatus unknownNCT02013232Not applicable
• Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course SchizophreniaCompletedNCT02011750Phase 4
• Psychosis-Associated Neuroinflammation in SchizophreniaCompletedNCT02009826
• Assessment of Adverse Events in a Naive Pediatric Population Treated With an AntipsychoticCompletedNCT02007928Not applicable
• eVAluatIon of OLanzapine TreatmEnTCompletedNCT02006862
• Memantine add-on for Cognitive and Negative Symptoms of SchizophreniaStatus unknownNCT02001103Phase 3
• Simvastatin Addition for Patients With Recent-onset SchizophreniaCompletedNCT01999309Phase 3
• Emotional Intelligence in Schizophrenia and Bipolar-I- DisorderCompletedNCT01998516
• Critical Time Intervention-Task Shifting: Randomized Controlled TrialCompletedNCT01995864Not applicable
• Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With SchizophreniaCompletedNCT01994473Phase 1
• Cognitive Remediation of Schizophrenia in a Community Mental Health SettingCompletedNCT01988714Not applicable
• Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I DisorderWithdrawnNCT01981811Phase 2
• Antismoking Effects of Electronic Cigarettes in Subjects With Schizophrenia and Their Potential Influence on Cognitive Functioning.WithdrawnNCT01979796Not applicable
• A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With LurasidoneCompletedNCT01979679Phase 3
• Neuroendocrine and Immune Response to Stress in SchizophreniaCompletedNCT01975584Not applicable
• Community-Based Cognitive Training in Early SchizophreniaCompletedNCT01973270Not applicable
• Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype CharacteristicsCompletedNCT01972711Phase 1
• Transcranial Direct Current Stimulation Influences on Cognitive Inhibition in SchizophreniaTerminatedNCT01971073Not applicable
• Biological Evaluation of Dietary Supplement Liposomal GlutathioneCompletedNCT01967667Not applicable
• A Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia to Describe Medical Resource Utilization and Burden of IllnessCompletedNCT01959659
• Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia SubjectsCompletedNCT01952132Phase 2
• Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled StudyTerminatedNCT01948999Not applicable
• Bio-equivalence Study Between SAPHRIS and AsenapineCompletedNCT01948024Phase 1
• A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With SchizophreniaCompletedNCT01947803Phase 4
• Famotidine in SchizophreniaStatus unknownNCT01946295Phase 2/3
• Stem Cell Research on Subjects at Genetic High Risk for SchizophreniaCompletedNCT01943175
• Linagliptin in Schizophrenia PatientsTerminatedNCT01943019Phase 1
• A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With SchizophreniaCompletedNCT01942382Phase 1
• Navigated αTMS in Treatment-resistant SchizophreniaActive, not recruitingNCT01941251Not applicable
• A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With SchizophreniaCompletedNCT01940159Phase 1
• Relapse Prevention in First Episode Schizophrenia: a 5 Year TrialStatus unknownNCT01936220Not applicable
• Effects of Varenicline on Plasticity in SchizophreniaCompletedNCT01934023Phase 2
• Randomized Controlled Trial of a Gluten Free Diet In Patients With Schizophrenia Who Are Gliadin-PositiveCompletedNCT01927276Not applicable
• A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital SettingCompletedNCT01926912
• Thinking Skills for Work in Severe Mental IllnessCompletedNCT01926613Not applicable
• Early Medication Discontinuation and Long-term Clinical Outcome in FEPCompletedNCT01926340
• A PET Study With RO5545965 in Healthy Male VolunteersCompletedNCT01923025Phase 1
• Computerised Interventions for Thinking and Anxiety in Delusions (CITADEL) TrialCompletedNCT01920685Not applicable
• Interventions to Improve Functional Outcome and Persistent Symptoms in SchizophreniaCompletedNCT01915017Not applicable
• Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®TerminatedNCT01908192Phase 2/3
• Phosphatidylcholine Supplementation in InfantsWithdrawnNCT01905605Phase 1/2
• Social Dysfunction and Brain Dysfunction in Patients With SchizophreniaStatus unknownNCT01903915
• Cognitive Remediation in SchizophreniaStatus unknownNCT01903707Not applicable
• Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable SchizophreniaTerminatedNCT01900522Phase 1
• The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia.CompletedNCT01897064Not applicable
• Cognitive Remediation and Sheltered Employment in SchizophreniaCompletedNCT01891929Not applicable
• Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT01888107Phase 3
• Auditory Verbal Hallucinations in SchizophreniaCompletedNCT01886417
• A RCT Study in Schizophrenia Relapse PreventionStatus unknownNCT01885923Not applicable
• N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in SchizophreniaCompletedNCT01885338Phase 1
• rTMS for Working Memory Deficits in SchizophreniaCompletedNCT01880255Not applicable
• Occupational Therapy in the Rehabilitation of Executive Functions in Patients With SchizophreniaStatus unknownNCT01879956Not applicable
• Yoga as Cognitive Remediation in SchizophreniaCompletedNCT01879709Not applicable
• Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With PsychosisCompletedNCT01878513Not applicable
• tRNS in Anterior Cingulate Cortex Reduces Craving Over Dual Pathology PatientsCompletedNCT01876524Not applicable
• Brief Culturally Adapted Cognitive Behavior Therapy for PsychosisCompletedNCT01876056Not applicable
• Open-label Study of Curcumin C-3 Complex in SchizophreniaCompletedNCT01875822Phase 1/2

← Schizophrenia overview